1 BTC
=
- USD
Celularity Inc. Class A Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Celularity Inc. Class A Common Stock
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
Market Statistics
Trading Metrics
How to Buy CELU
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy CELU
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesCelularity Inc. received a notification from Nasdaq on May 27, 2026, indicating non-compliance with Listing Rule 5250(c)(1) due to delayed filing of its Quarterly Report on Form 10-Q for Q1 2026. The company has until July 28, 2026, to submit a compliance plan, with a potential extension until November 16, 2026. Trading of the stock continues unaffected, and the company is working to file the report and regain compliance.
NexGel (NASDAQ: NXGL) agreed to acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity (NASDAQ: CELU). The transaction is expected to nearly triple NexGel's annual revenue to approximately $35 million in 2026 and make the company immediately profitable. The portfolio includes six commercial-stage products focused on tendon repair, skin grafts, and bone growth with over a decade of clinical use and existing insurance reimbursement pathways.
Celularity Inc. (CELU) announced that it did not timely file its Q1 2025 financial report, leading to a Nasdaq non-compliance notice. The company has 60 days to submit a plan to regain compliance and may be granted an extension until November 2025 if the plan is accepted.